Revolade Indications/Uses


Novartis Oncology


Full Prescribing Info
Revolade is indicated: for the treatment of previously treated adult and pediatric patients 1 year and older with immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis to increase platelet counts and reduce or prevent bleeding; in patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia to: enable the initiation of interferon based therapy, optimize interferon based therapy; in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia (first-line SAA); for the treatment of cytopenias in patients with severe aplastic anemia (refractory SAA) who have had an insufficient response to immunosuppressive therapy.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in